Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
|Articles|July 20, 2015
The Employee Profile in China R&D
Pharmaceutical companies are currently targeting the emerging markets of China and Africa for their future expansion, with the highest investment - USD 5.32 billion - just in China alone.
Advertisement
Pharmaceutical companies are currently targeting the emerging markets of China and Africa for their future expansion, with the highest investment - USD 5.32 billion - just in China alone. Mathini Ilancheran, Katherine Ni and Juanjo Cardona analyse recent recruitment patterns and talent profiles in this
Advertisement
Related to this article
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
Advertisement
Advertisement
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
3
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
4
Caution and Pharma’s AI Adoption: Understanding the Reasons Behind Uneven Uptake
5